Our findings align with previous studies demonstrating that PARG depletion enhances the efficacy of chemotherapeutic agents in melanoma, ovarian cancer, glioblastoma, and head and neck cancer.43, 44, 45, 46. Here, PARG is linked to head and neck cancer.